Establishment Of A Biomarker To Test Molecular Risk Of Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$834,448.00
Summary
Less than 20% of patients live 5 years after a diagnosis of gastric cancer (GC). This is due to the advanced stage at the time of diagnosis. We have no markers to monitor therapy of cancer. This proposal aims to use next generation sequencing to find specific genetic changes in a persons tumour that can be used to monitor therapy. We aim to use the same technology to group patients into high-risk or low risk for development of GC. This will allow specific screening only for those at high-risk.
Bridging The GAPP Between The Laboratory And Clinic To Prevent Gastric Adenocarcinoma And Proximal Polyposis Of The Stomach (GAPPS).
Funder
National Health and Medical Research Council
Funding Amount
$724,877.00
Summary
Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS) is an inherited form of gastric cancer. Affected patients develop a large number of gastric polyps and are at risk of gastric cancer in their 30s. The only effective treatment is to surgically remove the stomach. Gastrectomy is, however, associated with significant post-operative complications. We will use laboratory and mouse models of GAPPS to identify acceptable new approaches to prevent cancer in these patients.
Regulation Of Gastric Tumour Invasion And Growth By Gp130 Activating Cytokines.
Funder
National Health and Medical Research Council
Funding Amount
$625,642.00
Summary
Gastric cancer is a major cause of morbidity and death worldwide. We have previously established a very informative animal model of this disease which has facilitated a new understanding of the diverse role of the IL-6 family of cytokines in regulating gastric tumour growth and dissemination to distant organs. This proposal will focus on how the main members of this cytokine family, namely IL-6 and IL-11, inhibit gastric tumour invasion to other organs, and promote tumour growth respectively . A ....Gastric cancer is a major cause of morbidity and death worldwide. We have previously established a very informative animal model of this disease which has facilitated a new understanding of the diverse role of the IL-6 family of cytokines in regulating gastric tumour growth and dissemination to distant organs. This proposal will focus on how the main members of this cytokine family, namely IL-6 and IL-11, inhibit gastric tumour invasion to other organs, and promote tumour growth respectively . An understanding of these processes will aid in designing therapeutic interventions specific for each cytokine and which may lead to drugs aimed at limiting or reversing this disease.Read moreRead less
Understanding The Relationship Of Incretin Hormones, Gastric Emptying And Reactive Hypoglycaemia
Funder
National Health and Medical Research Council
Funding Amount
$132,743.00
Summary
Low blood glucose levels following a meal occur frequently in otherwise healthy people and those who have had surgery for weight loss. It affects quality of life adversely and current management is unsatisfactory. The proposed studies will use sophisticated techniques to evaluate the roles of the rate of stomach emptying and the so-called 'incretin' hormones which stimulate the release of insulin after a meal. The outcomes will have major implications for more rational management.
Structural Basis For Helicobacter Pylori Adhesion To Host Epithelial Cells
Funder
National Health and Medical Research Council
Funding Amount
$665,328.00
Summary
The aim of this grant is to understand how the bacteria that cause gastric cancer and ulcers interact with the cells that line the stomach. This information will be used to develop new treatments to combat disease.
Skin cancer affects 60% of Australians. Nicotinamide (vitamin B3) prevents many of sunlight’s damaging effects and reduces premalignant keratoses by 35% compared to placebo in sun-damaged individuals. We now need to test whether nicotinamide can prevent skin cancer. Skin cancer patients will receive nicotinamide or placebo for 12 months and new cancers will be counted in each group. Nicotinamide is safe, widely available and an exciting opportunity for cost-effective skin cancer prevention.